Epoetin Alfa,
Brand names: Epogen · Active ingredient: Epoetin
In short: Epogen is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion. Epogen is indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg/week in patie
What is Epoetin Alfa, used for?
Epogen is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and not on dialysis to decrease the need for red blood cell (RBC) transfusion.
Epogen is indicated for the treatment of anemia due to zidovudine administered at ≤ 4200 mg/week in patients with HIV infection with endogenous serum erythropoietin levels of ≤ 500 mUnits/mL.
Epogen is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy.
Epogen is indicated to reduce the need for allogeneic RBC transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dL who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. Epogen is not indicated for patients who are willing to donate autologous blood pre-operatively.
Epogen has not been shown to improve quality of life, fatigue, or patient well-being.
Epogen is not indicated for use:
In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy.
In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure.
In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion. …
⚠ Boxed warning (FDA's strongest warning)
Chronic Kidney Disease:
In controlled trials, patients with chronic kidney disease (CKD) experienced greater risks for death, serious
adverse
cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target
a
hemoglobin level
of greater than 11 g/dL
.
No trial has identified a hemoglobin target level, E
SA
dose, or dosing strategy that does not increase these risks
.
Use the lowest Epogen dose sufficient to reduce the
need for
red blood cell (RBC) transfusions
.
Cancer:
ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in
clinical studies
of
patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers
.
To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC
transfusions
.
Use ESAs only for anemia
from
myelosuppressive chemotherapy
.
ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure
.
Discontinue following the completion of a chemotherapy course
.
Perisurgery:
Due to increased risk of Deep Venous Thrombosis (DVT), DVT
prophylaxis is recommended
.
Epoetin Alfa, dosage
Evaluation of Iron Stores and Nutritional Factors
Evaluate the iron status in all patients before and during treatment. Administer supplemental iron therapy when serum ferritin is less than 100 mcg/L or when serum transferrin saturation is less than 20%. The majority of patients with CKD will require supplemental iron during the course of ESA therapy.
Monitoring of Response to Therapy
Correct or exclude other causes of anemia (e.g., vitamin deficiency, metabolic or chronic inflammatory conditions, bleeding, etc.) before initiating Epogen. Following initiation of therapy and after each dose adjustment, monitor hemoglobin weekly until the hemoglobin level is stable and sufficient to minimize the need for RBC transfusion.
Selection of Formulation
In pregnant women, lactating women, neonates, and infants use only single-dose vials (the benzyl alcohol-free formulation) [see Contraindication
s
(
4
) and Use in Specific Populations (
8.1
,
8.2
, and
8.4
)].
In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered ESAs to target a hemoglobin level of greater than 11 g/dL. No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks. Individualize dosing and use the lowest dose of Epogen sufficient to reduce the need for RBC transfusions . Physicians and patients should weigh the possible benefits of decreasing transfusions against the increased risks of death and other serious cardiovascular adverse reactions .
For all patients with CKD:
When initiating or adjusting therapy, monitor hemoglobin levels at least weekly until stable, then monitor at least monthly. When adjusting therapy consider hemoglobin rate of rise, rate of decline, ESA responsiveness and hemoglobin variability. A single hemoglobin excursion may not require a dosing change.
Do not increase the dose more frequently than once every 4 weeks. Decreases in dose can occur more frequently. Avoid frequent dose adjustments.
If the hemoglobin rises rapidly (e.g., more than 1 g/dL in any 2-week period), reduce the dose of Epogen by 25% or more as needed to reduce rapid responses.
For patients who do not respond adequately, if the hemoglobin has not increased by more than 1 g/dL after 4 weeks of therapy, increase the dose by 25%.
For patients who do not respond adequately over a 12-week escalation period, increasing the Epogen dose further is unlikely to improve response and may increase risks. Use the lowest dose that will maintain a hemoglobin level sufficient to reduce the need for RBC transfusions. Evaluate other causes of anemia. Discontinue Epogen if responsiveness does not improve. …
How to take Epoetin Alfa, — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Inform patients:
Of the increased risks of mortality, serious cardiovascular reactions, thromboembolic reactions, stroke, and tumor progression .
To undergo regular blood pressure monitoring, adhere to prescribed anti-hypertensive regimen and follow recommended dietary restrictions.
To contact their healthcare provider for new-onset neurologic symptoms or change in seizure frequency.
Of the need to have regular laboratory tests for hemoglobin.
Risks are associated with benzyl alcohol in neonates, infants, pregnant women, and lactating women .
Instruct patients who self-administer Epogen of the:
Importance of following the Instructions for Use.
Dangers of reusing needles, syringes, or unused portions of single-dose vials.
Proper disposal of used syringes, needles, and unused vials, and of the full container.
EPOGEN® (epoetin alfa)
Manufactured by:
Amgen Inc.One Amgen Center DriveThousand Oaks, CA 91320-1799 U.S.A.U.S. License Number 1080
©1989-2018, 2024 Amgen Inc. All rights reserved.
1xxxxxx- v35
Warnings & precautions
Do not take this medicine if: Epogen is contraindicated in patients with:
Uncontrolled hypertension
Pure red cell aplasia (PRCA) that begins after treatment with Epogen or other erythropoietin protein drugs
Serious allergic reactions to Epogen
Epogen from multiple-dose vials contains benzyl alcohol and is contraindicated in:
Neonates, infants, pregnant women, and lactating women [see
Warnings and Precautions (
5.9
),
Use in Specific Populations (
8.1
,
8.2
,
8.4
)].
In controlled clinical trials of patients with CKD comparing higher hemoglobin targets (13 – 14 g/dL) to lower targets (9 - 11.3 g/dL), Epogen and other ESAs increased the risk of death, myocardial infarction, stroke, congestive heart failure, thrombosis of hemodialysis vascular access, and other thromboembolic events in the higher target groups.
Using ESAs to target a hemoglobin level of greater than 11 g/dL increases the risk of serious adverse cardiovascular reactions and has not been shown to provide additional benefit . Use caution in patients with coexistent cardiovascular disease and stroke . Patients with CKD and an insufficient hemoglobin response to ESA therapy may be at even greater risk for cardiovascular reactions and mortality than other patients. A rate of hemoglobin rise of greater than 1 g/dL over 2 weeks may contribute to these risks.
In controlled clinical trials of patients with cancer, Epogen and other ESAs increased the risks for death and serious adverse cardiovascular reactions. These adverse reactions included myocardial infarction and stroke.
In controlled clinical trials, ESAs increased the risk of death in patients undergoing coronary artery bypass graft surgery (CABG) and the risk of deep venous thrombosis (DVT) in patients undergoing orthopedic procedures.
The design and overall results of the 3 large trials comparing higher and lower hemoglobin targets are shown in Table 1. …
Epoetin Alfa, side effects
The following serious adverse reactions are discussed in greater detail in other sections of the label:
Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism
Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients with Cancer
Hypertension
Seizures
PRCA
Serious Allergic Reactions
Severe Cutaneous Reactions
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of other drugs and may not reflect the rates observed in practice.
Patients
with Chronic Kidney Disease
Adult
Patients
Three double-blind, placebo-controlled studies, including 244 patients with CKD on dialysis, were used to identify the adverse reactions to Epogen. In these studies, the mean age of patients was 48 years (range: 20 to 80 years). One hundred and thirty-three (55%) patients were men. The racial distribution was as follows: 177 (73%) patients were white, 48 (20%) patients were black, 4 (2%) patients were Asian, 12 (5%) patients were other, and racial information was missing for 3 (1%) patients.
Two double-blind, placebo-controlled studies, including 210 patients with CKD not on dialysis, were used to identify the adverse reactions to Epogen. In these studies, the mean age of patients was 57 years (range: 24 to 79 years). One hundred and twenty-one (58%) patients were men. …
About this medicine
Epoetin alfa is a 165-amino acid erythropoiesis-stimulating glycoprotein manufactured by recombinant DNA technology. It has a molecular weight of approximately 30,400 daltons and is produced by mammalian cells into which the human erythropoietin gene has been introduced. The product contains the identical amino acid sequence of isolated natural erythropoietin.
Epogen (epoetin alfa) injection for intravenous or subcutaneous administration is formulated as a sterile, clear, colorless liquid in vials in multiple formulations. Single-dose vials, formulated with an isotonic sodium chloride/sodium citrate-buffered solution, are supplied in multiple strengths. Each single-dose 1 mL vial contains 2,000, 3,000, 4,000, or 10,000 Units of epoetin alfa, Albumin (Human) (2.5 mg), citric acid (0.06 mg), sodium chloride (5.9 mg), and sodium citrate (5.8 mg) in Water for Injection, USP (pH 6.9 ± 0.3). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1f2d0b28-9cc5-4523-80b8-637fdaf3f7a5. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate